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Atypical protein kinase C (aPKC) is a key apical-basal
polarity determinant and Par complex component.
It is recruited by Par3/Baz (Bazooka in Drosophila)
into epithelial apical domains through high-affinity
interaction. Paradoxically, aPKC also phosphorylates
Par3/Baz, provoking its relocalization to adherens
junctions (AJs). We show that Par3 conserved region
3 (CR3) forms a tight inhibitory complexwith a primed
aPKC kinase domain, blocking substrate access. A
CR3 motif flanking its PKC consensus site disrupts
the aPKC kinase N lobe, separating P-loop/aB/aC
contacts. A second CR3motif provides a high-affinity
anchor. Mutation of either motif switches CR3 to an
efficient in vitro substrate by exposing its phospho-
acceptor site. In vivo, mutation of either CR3 motif
alters Par3/Baz localization from apical to AJs. Our
results reveal how Par3/Baz CR3 can antagonize
aPKC in stable apical Par complexes and suggests
that modulation of CR3 inhibitory arms or opposing
aPKCpockets would perturb the interaction, promot-
ing Par3/Baz phosphorylation.
INTRODUCTION
Epithelial tissues are composed of sheets of polarized cells that
are connected by adherens junctions (AJs) (Laprise and Tepass,
2011; St Johnston and Ahringer, 2010; Suzuki and Ohno, 2006).
The plasma membrane of epithelial cells is segregated into
apical and basolateral domains, with a prominent belt of AJs
located at the interface of these two domains (Figures S1A and
S1B). The atypical protein kinase C (aPKC in Drosophila or384 Developmental Cell 38, 384–398, August 22, 2016 ª 2016 The A
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and the small guanosine triphosphatase Cdc42 are three essen-
tial determinants of apical membrane identity in both Drosophila
and mammals (Fletcher et al., 2012; Harris and Tepass, 2008;
Hutterer et al., 2004; Izumi et al., 1998; Joberty et al., 2000; Lin
et al., 2000; Wodarz et al., 2000). The aPKC-Par6-Cdc42 assem-
bly can form a larger stable complex with Par3/Baz (Bazooka
[Baz] in Drosophila) (known as the Par complex) at the apical
membrane (Izumi et al., 1998; Joberty et al., 2000; Lin et al.,
2000; Wodarz et al., 2000). Association of Par3 with the baso-
lateral membrane is prevented by phosphorylation of its lipid-
binding domain by the basolateral kinase Par1 (Benton and
St Johnston, 2003b).
Importantly, a distinct pool of Par3/Baz can also segregate
away from apical aPKC-Par6-Cdc42 and localize to AJs (Mor-
ais-de-Sa et al., 2010; Walther and Pichaud, 2010). The role of
Par3/Baz at AJs is thought to be essential as it involves
defining the position of AJs during the establishment of epithe-
lial polarity (Wang et al., 2012b) and possibly also remodeling
of AJs as tissues undergo morphogenetic change (Walther
and Pichaud, 2010). The regulation of this switch of Par3/Baz
subcellular localization from the apical membrane to AJs has
been shown in Drosophila to be dependent on aPKC phos-
phorylating Par3/Baz on serine 980 in vivo (Morais-de-Sa
et al., 2010; Walther and Pichaud, 2010). This site is within a
consensus PKC phosphorylation R-X-S-J motif and is equiv-
alent to serine 827 of human Par3 (Figure S1D), both sites
map to Par3/Baz conserved region 3 (CR3), a site of regulated
protein interaction (Nagai-Tamai et al., 2002). However, how
Par3/Baz switches from being a stable binding partner of
aPKC in the Par complex to being a substrate of aPKC that
segregates away from the Par complex remains unclear. In
mammalian cells, a similar conundrum exists whereby Par3
is critical for the recruitment of PKCi to the apical membrane
and is known to be an in vivo substrate of PKCi, but loss of
Par3 in transformed epithelial cells can lead to PKCi activationuthor(s). Published by Elsevier Inc.
commons.org/licenses/by/4.0/).
and can result in breast tumorigenesis and metastasis (McCaf-
frey and Macara, 2009; McCaffrey et al., 2012).
One complication in understanding the role of Par3/Baz in
Drosophila epithelia is the presence of another key apical deter-
minant, Crumbs (Crb) (Tepass, 1996). Like Par3/Baz, Crb can
localize apically in a complex with Stardust (Sdt) (Bilder et al.,
2003; Roh et al., 2003; Tanentzapf and Tepass, 2003; Tepass,
1996) and aPKC-Par6-Cdc42 (called the Crb complex) (Fletcher
et al., 2012; Harris and Tepass, 2008; Morais-de-Sa et al., 2010).
Par3/Baz and Crb-Sdt can therefore act in a semi-redundant
fashion to specify the apical domain in Drosophila, such that
either Par3/Baz or Crb-Sdt is usually sufficient to maintain polar-
ity in Drosophila (Fletcher et al., 2012; Tanentzapf and Tepass,
2003). Similarly, Willin, a FERM-domain protein, has been impli-
cated in another Par3-independent apical domain recruitment
mechanism for Par6-aPKC (Ishiuchi and Takeichi, 2011). The
presence of Crb has been shown to promote Par3/Baz localiza-
tion to AJs (Morais-de-Sa et al., 2010; Walther and Pichaud,
2010). However, in the absence of Crb, some Par3/Baz can still
be phosphorylated by aPKC on S980 so that it localizes to AJs
(Morais-de-Sa et al., 2010). These findings indicate that individ-
ual Par3/Bazmolecules can localize either apically or junctionally
without requiring any input from Crb. Thus, the paradoxical dual
role of Par3/Baz as either a Par complex component or an aPKC
substrate appears to be an emergent property of these mole-
cules themselves, although it is still uncertain how this property
arises.
aPKC isoforms PKCi and PKCz have regulatory regions
distinct from those of other PKC isozymes, but share a conserved
catalytic protein kinase domain (Parker and Murray-Rust, 2004).
They are not responsive to diacylglycerol and have less well-
defined activators (Limatola et al., 1994). Like many protein
kinases, activation of aPKC requires activation-loop phosphory-
lation and an aC-helix conformation compatible with Lys-Glu
salt-bridge formation to bind ATP and serve to align residues
within the R spine (Kornev et al., 2008). Functionally validated
aPKC substrates include Par3, LLGL2, ROCK1, and MARK2,
and the Hippo pathway component Kibra (Betschinger et al.,
2005;Buther et al., 2004;Hurov et al., 2004; Ishiuchi andTakeichi,
2011). Sequences flanking the phospho-acceptor site in each
aPKC substrate are rich in basic residues consistent with baso-
philic AGC kinase consensus sites derived from short peptide
substrates (4–14 residues) (https://www.kinexus.ca). In these
contexts aPKC phosphorylation inactivates substrates with
basophilic membrane-binding motifs with embedded phosphor-
ylation sites such that theyaredisplaced frommembranes (Bailey
and Prehoda, 2015).
Here, we describe how Par3 CR3 recognizes and inhibits
a nucleotide-occupied primed PKCi. Two Par3 CR3 motifs
flanking its PKC consensus site engage pockets within the
PKCi kinase domain, one of which disrupts crucial N-lobe con-
tacts required for catalytic activity. A second contact used by
both aPKC inhibitors and substrates provides a high-affinity
anchor point through a Phe-X-Arg motif. Together, both motifs
cooperate to block aPKC substrate access and prevent phos-
pho-transfer to Par3 CR3. Mutation of either motif switches
Par3 from an inhibitor to an efficient substrate in vitro and redis-
tributes equivalent Bazooka mutants to AJs in vivo. These data
are consistent with high-affinity inhibitory interactions betweenPar3/Baz and aPKC preventing Par3/Baz phosphorylation and
thereby promoting stable complex formation and apical locali-
zation. Modulation of the CR3 inhibitory arm by phosphorylation
or engagement of the aPKC pocket by partner proteins would
switch Par3/Baz to a more transient type of interaction, conse-
quently enabling efficient phosphorylation of Par3/Baz by aPKC
and subsequent relocalization to AJs.
RESULTS
The Par3 CR3 Region Inhibits Nucleotide-Bound Primed
PKCi Kinase Domain through Two Flanking Arm
Contacts
The human Par3 conserved region 3 (CR3, covering residues
816–834, defined hereafter as Par3CR3) is able to bind to PKCi
(Nagai-Tamai et al., 2002) and contains a phospho-acceptor
site (P site) at residue serine 827 known to be phosphorylated
by PKCi (Figures 1A and 1B). To characterize its interaction
with PKCi we purified a ‘‘primed’’ active form of the human
PKC-iota kinase domain (referred to as PKCiKD-2P) and a
partially primed low-activity form (referred to as PKCiKD-1P),
referring to the status of the two ‘‘priming’’ phosphorylation sites
at pT412 and pT564 (Figures 1A and S2A–S2C). We then probed
how efficiently they were able to phosphorylate Par3CR3. Surpris-
ingly, we found that Par3CR3 strongly inhibited the catalytic
activity of PKCiKD-2P in vitro and could competitively block
phosphorylation of a model substrate peptide, with an apparent
50% inhibitory concentration (IC50) of 0.45 ± 0.18 mM. In
contrast, peptides from other known aPKC substrates such as
Par1 were efficiently phosphorylated and were unable to inhibit
(Figures 1B–1D). Using a fluorescence anisotropy assay, we
found that the Par3CR3 binds to PKCiKD-2P with submicromolar
affinity (KD of 0.47 ± 0.09 mM), as does an S827A mutant (KD of
0.97 ± 0.07 mM) (Figure 1E). PKCiKD-2P is a good surrogate
for an activated Par complex containing Par6-PKCi-Cdc42
complex that exhibits high activity in vitro and is also potently in-
hibited by Par3CR3 (data not shown). In contrast, PKCiKD-1P was
not inhibited to the same extent and had amuch lower affinity for
Par3CR3 (compare Figures 1D, S2D, and S2E). We conclude that
a high-affinity Par3CR3 targets PKCiKD-2P and inhibits its cata-
lytic activity.
To understand how Par3CR3 could inhibit PKCiKD-2P, we
determined the 2.0-A˚ crystal structure of a longer Par3 peptide
(residues 816–841) bound to PKCiKD-2P and Mg-AMPPNP
(adenylyl imidodiphosphate) (Figures 2A and S3A; Table 1).
The Par3CR3 peptide is well ordered in this structure and contains
seven intramolecular hydrogen bonds (Figure S3B). It engages
PKCiKD-2P by adopting a ‘‘staple’’-shaped conformation with
two arms that flank the S827Par3 phospho-acceptor site. Each
arm binds in close proximity to opposite ends of the nucleotide,
suggesting that recognition of aPKC is driven by nucleotide
occupancy. The relative orientation of N and C lobes indicates
a ‘‘closed’’ rather than ‘‘open’’ conformation. Par3CR3 contacts
extend from a pocket beneath the ribose-binding pocket of
PKCi (site 1), across the G helix (site 2) through to the activation
loop, aB and aC helices of the PKCiKD-2P N lobe (site 3) (Figures
2A and 2B). A total surface area of more than 1,305 A˚2 is buried
within the complex, consistent with a high-affinity inhibitory inter-
action. The nucleotide cleft is occupied by an Mg-AMPPNPDevelopmental Cell 38, 384–398, August 22, 2016 385
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Figure 1. Par3/Baz CR3-Mediated Inhibition of aPKC In Vitro
(A) Domain structure of Par3 and PKCi and location of key phosphorylation sites in each. For more detail on aPKC and Par3/Baz subcellular localization and how
aPKC phosphorylation of Par3/Baz switches Par3/Baz localization from the apical membrane to AJs, see Figure S1.
(B) Sequence alignment of human Par3 CR3 region with Par1 highlighting known phosphorylation sites (red).
(C) Par3CR3 inhibits PKCiKD-2P catalytic activity in an in vitro kinase assay, whereas a Par1-derived peptide is a substrate.
(D) The IC50 curves for Par3CR3.
(E) Affinity of fluorescein-labeled Par3CR3 for PKCiKD-2P measured by fluorescence anisotropy.
RFU, relative fluorescence units; WT, wild-type. Data are plotted as mean ± SEM. See also Figure S2 for purification and further characterization of PKCiKD-2P.nucleotide (Figure 2C). The conserved nucleotide-coordi-
nating lysine (K283PKCi) forms a salt bridge with the conserved
aC-helix glutamate (E302PKCi) side chain found inmany active ki-
nase conformers (Kornev et al., 2008). The terminal g-phosphate
of AMPPNP is not observed in the structure, consistent with
AMPPNP being rapidly hydrolyzed under the crystallization
conditions (see Experimental Procedures). A magnesium ion,
equivalent to Mg2 of PKA, is present, bridging both the a and
b phosphates of AMPPNP (Adams and Taylor, 1993; Zheng
et al., 1993). The Mg1 ion is not present, as frequently found in
ADP-complexed AGC kinase structures.
The amino-terminal part of Par3CR3 binds to site 1 (PKCiKD-2P
kinase C lobe) through an F-X-R motif at positions 9 (F9)
and 7 (R7) defined relative to the phospho-acceptor (P site)
at serine 0 (equivalent to S827 of human Par3). F9 lies deep
within a hydrophobic cleft formed by M341PKCi, M344PKCi, and
L381PKCi beneath the nucleotide pocket (Figure 2C). In addition,
the side chain of R7 forms a salt bridge to D339PKCi, just
beneath the ribose ring of the AMPPNP, while that of R2 en-
gages conserved residues Y419PKCi and E445PKCi (Figure 2C).
As this motif does not appear to directly perturb aPKC catalytic
residues, we refer to this element hereafter as the ‘‘affinity arm’’
of Par3CR3 (Figure 2C).
From site 1, the Par3CR3 backbone adopts two consecutive
type II reverse turns with positive phi-main-chain angles at E6
and G3. This leads into site 2, positioned to contact the G helix
through residue F4 that displaces and disorders the aPKC-spe-
cific kinase insert (residues 455PKCi to 466PKCi). The phospho-
acceptor serine-0 hydroxyl hydrogen bonds to side chains
of D378PKCi, K380PKCi, and T416PKCi, preventing a catalytically386 Developmental Cell 38, 384–398, August 22, 2016competent orientation for nucleophilic attack on the ATP g-phos-
phate. Glycine-rich loop residues S264PKCi and Y265PKCi side
chains contact the CR3 main-chain atoms near the P site,
as does the activation-loop main chain, to orient the Par3CR3
peptide and position the M+1 side chain into the known P+1
AGCkinase hydrophobic pocket (Figure 2C) (Pearce et al., 2010).
Site 3 contains carboxy-terminal flanking residues to the P site
stretching from S+2 to T+6. We define this portion of Par3CR3 as
the ‘‘inhibitory arm,’’ as it directly perturbs an active PKCiKD-2P
N-lobe conformation (discussed later). Residue K+4 directly con-
tactspT412PKCiof theactivation loopenhancing the recognitionof
mature, primed PKC iKD-2P, but importantly not a partially primed
PKCiKD-1P. Crucially, the R+5 side chain is buried within a hydro-
phobic pocket beneath the regulatoryaChelix. The pocket is lined
by side chains fromY265PKCi on the glycine loop andW298PKCi of
the aC helix, each making p-stacking interactions with the guani-
dino group of R+5 (Figures 2C and 3A). Both aromatic side chains
are unique to aPKC isozymes from Drosophila to mammals.
Finally, T+6 (equivalent to T833Par3, a known ROCK-driven phos-
phorylation site discussed later) lies adjacent to an acidic patch
within the aB helix making side-chain and main-chain contacts
to D295PKCi and a Mg ion (Figures 2C and 3A). Overall, the struc-
ture reveals that the Par3CR3 clamp involves an ‘‘inhibitory arm’’
and an ‘‘anchoring arm,’’ which together recognize and inhibit a
nucleotide-bound PKCiKD-2P conformer.
Comparison of Par3CR3-Inhibited PKCi Complex with an
Active PKCi Conformer Reveals the Basis for Inhibition
To fully understand how Par3CR3 inhibits PKCi and disrupts its
activated state, we determined the structure of an ‘‘active’’
Table 1. Data Collection and Refinement Statistics
PKCiKD-2P/Par3 CR3 Peptide/
Mg-AMPPNP PKCiKD-2P/AMPPCP
PKCiKD-2P/Mn-ADP/AlF3/FXR-Short
Peptide
Data Collection
Space group P3121 P212121 P212121
Cell Dimensions
a, b, c (A˚) 82.0, 82.0, 90.8 61.1, 65.1, 87.4 79.0, 84.2, 111.8
a, b, g () 90, 90, 120 90, 90, 90 90, 90, 90
Resolution (A˚) 45.45–1.95 (2.06–1.95) 52.23–1.79 (1.84–1.79) 67.28–3.25 (3.43–3.25)
Completeness (%) 99.6 (997.5) 100 (100) 99.6 (99.9)
Multiplicity 8.2 (7.0) 9.5 (9.6) 3.8 (3.6)
Rmeas (%)pim 9.0 (64.0) 17.3 (200) 20.0 (55.1)
Rp.i.m. (%)pim 3.1 (23.3) 5.6 (63.4) 9.9 (27.5)
<I>/<sI> 15.0 (3.0) 8.2 (1.4) 6.3 (2.5)
Total no. of observations 216,286 (25,839) 323,684 (23,802) 46,484 (6,806)
Total no. unique 26,242 (3,689) 33,998 (2,474) 1,200 (1,753)
Structure Refinement
Za 1 1 2
Reflections 25,607 33,825 12,145
Rwork (%) 15.0 18.8 25.66
Rfree (%) 21.7 23.1 28.36
No. of protein atoms A = 2,719 A = 2,701 A = 2,527, B = 2,489, F = 100, G = 76
No. of ligand atoms B = 154, D = 66 B = 48 C = 27, D = 27, other = 27
No. of solvent atoms C = 2, E = 170, F = 14 C = 21, D = 244, E = 5, F = 8,
G = 18, I = 8
E = 25
Mean B Factor
Protein A = 26.1 A = 23.7 (A, B, F, G) = 44.00
Ligand B = 35.0, D = 29.5 B = 28.0 all (non-water) = 41.7
Solvent C = 45.6, E = 38.1, F = 45.5 C = 61.3, D = 35.7, E = 65.3,
F = 58.4, G = 46.1, I = 52.9
E = 32.0
RMSD bonds (A˚), angles () 0.008, 1.100 0.004, 0.765 0.003, 0.733
Ramachandran Plot (%)
Favored 98.0 97.6 94.5
Allowed 2.0 2.1 5.4
Outliers 0.0 0.3 0.15
where
A = protein
B = peptide
C = K+ ion
D = AMPPNP
E = water
F = glycerol
where
A = protein
B = AMPPCP
C = formate
D = water
E = imidazole
F = MPD
G = PEG
I = acetate
where
A, B = protein
F, G = peptide
C, D = ADP
E = water
RMSD, root-mean-square deviation; PEG, polyethylene glycol; MPD, 2-methyl-2,4-pentanediol.conformer of PKCi for comparison (Figure 3B). Previous struc-
tures of PKCi kinase domain (PDB: 3A8W and 4DC2) (Takimura
et al., 2010; Wang et al., 2012a) exhibited either a disordered or
displaced aB-aC loop (Figures 3C and 3D). We captured an
active mature PKCi conformation bound to the ATP analog
50-(b,g-adenylyl methylene)diphosphonate (AMPPCP) at 1.8 A˚
(Figure S3C and Table 1). This analog was resistant to hydrolysis
compared with AMPPNP. The structure has an ordered aB-aCloop and reveals side-chain contacts between Y265PKCi of
the P loop and D295PKCi of the aB-aC loop. This interaction sta-
bilizes Y265PKCi side-chain stacking with a rotamer of W298PKCi
from the aC helix (Figure 3B). Other PKC isoform structures have
a phenylalanine and cysteine, respectively, at these positions
(Grodsky et al., 2006; Leonard et al., 2011; Xu et al., 2004). Struc-
tural comparisons suggest that Par3CR3 inhibitory arm not only
separates P-loop contacts with aB-aC loop/aC helix but alsoDevelopmental Cell 38, 384–398, August 22, 2016 387
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Figure 2. Structural Basis for Par3/Baz CR3-Mediated Inhibition of aPKC
(A) Overall structure of PKCiKD-2P (gray surface) bound to Par3CR3 (green stick) with Mg-AMP-PNP shown as an orange surface and priming sites at T564 and
T412 indicated.
(B) Schematic representation of three sites of contacts between Par3CR3 and PKCiKD-2P. The known phospho-acceptor site at serine 0 is shown in red.
(C) Close up of the contacts between Par3CR3 peptide (green) and PKCiKD-2P (residues making contacts shown in blue). Hydrogen bonds between side chains or
main-chain atoms are shown as dashed red lines. Pink spheres represent magnesium ions.
See also Figures S3A and S3B for refined Par3CR3 electron density and intramolecular hydrogen bonds within Par3CR3.hijacks Y265PKCi and S264PKCi side chains to directly form
hydrogen bonds with CR3 main-chain atoms. Comparing the
Par3CR3 inhibitory complex with 1ATP (PKA bound to Mg-ATP
and PKI peptide) suggests that the R+5 side-chain guanidine
group lies close to the Mg2 ion of an active kinase conformation
(Adams and Taylor, 1993; Zheng et al., 1993), indicating another
layer of Par3CR3 disruption of an active PKCi conformation.
Furthermore, T+6 (equivalent to T833Par3), which makes direct
contact with D295PKCi, is a phospho-acceptor site targeted by
the ROCK kinase, leading to a disruption of PKCi interaction
with Par3 (Nakayama et al., 2008). This would predict, based
on our structural comparison, that modulation of the ‘‘inhibitory
arm’’ of Par3CR3 by ROCK kinase phosphorylation, or inaccessi-
bility of the pocket to which it binds, could influence whether
Par3 can inhibit PKCi or engages it as a substrate.
A Shared High-Affinity Anchor Motif Used by aPKC
Substrates and Inhibitors
Our Par3CR3-PKCiKD-2P inhibitory complex differs significantly
from a previous structure of an ATP-binding deficient and
partially primed PKCi K283R mutant (PKCiKD-1P, PDB: 4DC2)
bound to Par3CR3 (Wang et al., 2012a). In the absence of nucle-388 Developmental Cell 38, 384–398, August 22, 2016otide, Par3CR3 residues +3 to +7 were disordered and, therefore,
the CR3 region is lacking inhibitory site 3 contacts (Wang et al.,
2012a). Consistent with this, Par3CR3 is unable to potently inhibit
the partially primed PKCiKD-1P or bind with high affinity (Figures
S2D, S2E, and S4B). We present evidence that our Par3CR3-
PKCiKD-2P structure represents a Par3CR3-mediated inhibitory
complex of mature PKCi. However, the structure reported by
Wang et al. (2012a) most likely resembles a weaker and transient
Par3-PKCi interaction relevant to a protein kinase-substrate
interaction (Figure 4).
To explore and capture a substrate peptide bound to
PKCiKD-2P, we used an artificial substrate (FKRQGSVRRR,
referred to hereafter as F-X-Rshort peptide) (Figures S4A–S4E).
This efficient PKCi substrate closely resembles the aPKC
consensus motif identified from screening randomly oriented
peptide libraries by Cantley and co-workers (Nishikawa et al.,
1997). We therefore determined a crystal structure for F-X-Rshort
bound to PKCiKD-2P in the presence ofMn-ADP and AlF3, a tran-
sition-state analog (Figure S4E). Manganese ions corresponding
to Mg1 and Mg2 ions are present in the structure, and the AlF3
is positioned as expected to mimic the transition state for
the g-phosphate. Surprisingly, the structure revealed that the
A B
C D
Wang et al. 2012a
Figure 3. Close-Up View of the Par3 CR3
Inhibitory Arm Pocket Bound to PKCiKD-
2P with Other PKCiKD Structures
(A) Close up of the inhibitory R+5 hook of Par3CR3
clamped by side chains Y265PKCi (P loop) and
W298PKCi (aC helix) of PKCiKD-2P (gray cartoon,
major interaction residues are shown as blue
sticks). Key structural features of the PKCiKD-2P
are labeled. Hydrogen bonds between key side
chains are shown as dashed red lines.
(B) Close up of R+5 pocket in the active confor-
mation of AMPPCP-bound PKCiKD-2P structure.
Hydrogen bonds between key side chains are
shown as dashed red lines.
(C) Close up of R+5 pocket in the previously
solved ATP-bound PKCiKD-2P structure (PDB:
3A8W) (Takimura et al., 2010).
(D) Close up of PKCiKD-1P K283R mutant within
its ATP cleft (PDB: 4DC2) (Wang et al., 2012a).
See also Figure S3C for refined nucleotide analog
electron density and Figure S3D for a compar-
isonwith a chemical inhibitor-induced PKCiKD-2P
conformer.F-X-R motif at F5 and R3 engages precisely the same site 1
residue contacts (M341PKCi, M344PKCi and L381PKCi, and
D339PKCi) as the F9 and R7 contacts used by Par3CR3,
despite their different position in the primary sequence (Fig-
ure S4F). Moreover, the R3 side chain directly makes a
hydrogen bond with the ribose hydroxyl, perhaps sensing nucle-
otide occupancy. We also observe an R+2 side-chain bridging
contact between phospho-T412PKCi and G398PKCi main-chain
carbonyl, making two key hydrogen bonds with these groups.
We note that many aPKC substrates have an R+2 side chain,
suggesting that direct contact with a phosphorylated activa-
tion loop may reflect a common interaction made by aPKC
substrates.
From the Par3CR3 structure, it is evident that the F-X-Rshort
peptide does not inhibit PKCi because it lacks aC-terminal inhib-
itory motif (Figures 4 and S5). Consistent with this, the Par1 pep-
tide characterized as a good aPKC substrate also has an F-X-R
anchor and a validated aPKC phosphorylation site, but lacks
an obvious inhibitory motif (Figure 1C) (Hurov et al., 2004). In
contrast, a Kibra-derived peptide (residues 919–978) containing
a validated aPKC phosphorylation site has both an F-X-R motif
anchor and a K-R inhibitory motif. As such it is able to potentlyDevelopmeninhibit PKCi in vitro (Figures S5A–S5C),
consistent with reports of Kibra inhibiting
aPKC kinase activity in epithelial cells
(Yoshihama et al., 2011). Indeed a related
peptide from WWC2 protein, a poorly
characterized Kibra homolog, also in-
hibits PKCi in vitro (Figures S5A–S5C).
Taken together, these data indicate that
an F-X-R motif anchor amino-terminal
to an aPKC phosphorylation site can be
found in both aPKCsubstrates and inhib-
itors at variable lengths in their primary
sequence from the phospho-acceptor
site. Furthermore, the C-terminal inhibi-tory arm bearing a K-R-T motif is unique to aPKC protein inhibi-
tors such asPar3 andKibra, and canbe predictive of an inhibitory
function (WWC2).
Manipulating Par3 CR3 Flanking Arms In Vitro Switches
Par3 from an Inhibitor to an Efficient PKCi Substrate
Our results suggested that Par3 CR3 arms flanking the
consensus PKC phosphorylation site cooperate to inhibit
PKCi. To probe the individual contributions of each arm, we
characterized Par3CR3 substitutions at critical contact residues
in the affinity arm and the inhibitory arm for their impact on
Par3CR3 affinity for PKCi and ability inhibit kinase activity. Two
mutants were prepared: first, substitution of F-Q-R to A-Q-A in
the site 1 affinity arm, referred to as A-X-A hereafter; and second,
substitution of K-R-T to A-A-T of the site 3 inhibitory arm,
referred to as A-A-T. Consistent with our crystal structure, either
A-X-A or A-A-T mutation within Par3CR3 markedly reduce the
CR3-binding affinity for PKCiKD-2P, but without abolishing the
interaction entirely (Figures 5A and 5B). A phospho-S827Par3
peptide representing the PKCi reaction product bound poorly,
with affinity two orders of magnitude lower than in Par3CR3 (Fig-
ures 5A and 5B).tal Cell 38, 384–398, August 22, 2016 389
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Figure 4. Structural Comparison of aPKC-Substrate and aPKC-Inhibitor Interactions
(A) Top panel: cartoon depiction of the Par3CR3 (green) bound to PKCiKD-2P (omitted for clarity) highlighting the position of inhibitory7 and +5 arginine residues
flanking the nucleotide (gray sticks). Middle panel: schematic representation of the interaction sites of Par3CR3 with PKCiKD-2P. Bottom panel: close up of the R+5
pocket occupied by Par3CR3 and the Y265 and W298 clamp residues of PKCiKD-2P (gray). The known phospho-acceptor site at serine 0 is shown in red for all
panels.
(B) Top panel: cartoon depiction of the Par3CR3 (blue) bound to PKCiKD-1P K283R mutant (omitted for clarity) from Wang et al. (2012a) lacking inhibitory site 3
contacts, possibly reflecting a lower-affinity substrate-type interaction.Middle panel: schematic representation of the interaction sites of Par3CR3with PKCiKD-1P
K283Rmutant. Bottom panel: close up of the ‘‘closed’’ R+5 pocket in which the clamp residues Y265 andW298 make direct contact (PKCiKD-1P shown in pink).
(C) Top panel: cartoon depiction of the FXRshort (purple) bound to PKCiKD-2P,Mn-ADP, and AlF3. This artificial substrate lacks inhibitory site 3 contacts but shares
site 1 FXR motif. Middle panel: schematic representation of the interaction sites of FXRshort with PKCiKD-2P. Bottom panel: close up of the ordered portion of the
R+5 pocket including the glycine loop and Y265 but not the disordered W298 from the aC helix (PKCiKD-1P shown in orange).
See also Figures S4A–S4D for the design and characterization of FXRshort peptide. See Figures S4E and S4F for refined FXRshort peptide electron density and a
superposition of the Par3CR3 and FXRshort peptides bound to PKCiKD-2P.Surprisingly, the in vitro kinase assay demonstrated that
either an A-X-A or A-A-T mutation gave a substantial increase
in Par3CR3 phosphorylation by PKCiKD-2P, greatly enhancing
the apparent kcat values (Figures 5A and 5C). The large effects
observed for each mutant (57-fold for A-X-A Par3CR3 versus
18-fold A-A-T Par3CR3) suggest that these substitutions uncou-
ple the ability of Par3CR3 to inhibit PKCiKD-2P, resulting in access
to the PKC consensus site at S827Par3 and efficient phosphory-
lation by PKCiKD-2P. The magnitude of the increased kcat values
allowed the measurement of a KM for the A-X-A Par3CR3 sub-
strate (KM of 39 mM), which was not possible for wild-type
Par3CR3. Combining both site 1 and site 3 mutations (A-X-A +390 Developmental Cell 38, 384–398, August 22, 2016A-A-T) within Par3CR3 generated a very poor substrate that
was not detectably phosphorylated and had no measurable
interaction with PKCiKD-2P (data not shown). These data indi-
cate that while mutating either the anchoring arm or inhibitory
arm switches Par3CR3 to an efficient aPKC substrate, the re-
maining arm must contribute sufficient binding affinity (both are
basophilic) as mutating both arms generates a Par3CR3 that is
neither a substrate nor an inhibitor. These striking results are
also consistent with the notion that tight inhibitory binding of
Par3CR3 to PKCiKD-2P must prevent its phosphorylation while
weaker binding without the inhibitory interactions exposes its
PKC site, switching it to a highly efficient in vitro PKCi substrate.
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Figure 5. Reducing the Par3CR3 Affinity for PKCiKD-2P Promotes Efficient CR3 Phosphorylation In Vitro
(A) Summary table of kcat, KD, and KM constants between various Par3CR3 mutants and PKCiKD-2P. Data are presented as mean ± SEM. n.d., not determined.
(B) Binding curves for Par3CR3 and various Par3CR3 mutants determined by fluorescence polarization (color coded as in A).
(C) PKCiKD-2P catalytic activity kinetic rate constants for Par3CR3 and various Par3CR3mutants (color coded as in A). For further details of other inhibitory peptides
similar to Par3CR3, see Figure S5.
(D) Co-immunoprecipitation (IP) of full-length Myc-Par3 or mutants (Par3-A-X-A and Par3-A (S827A)) and GFP-PKCi from HCT-116 cells shows that the F-X-R to
A-X-A mutation dramatically reduces the interaction.
(E) Co-immunoprecipitation of GFP-PKCi or GFP-PKCi-D/D with Myc-Par3 also severely impairs the interaction. GFP-PKCi-D/D is a mutant replacing residues
D330/D373 that interact with the F-X-R motif by alanine.
(F) Immunoblot (IB) using a phospho-S827-specific antibody indicates that Par3 and Par3 A-X-A mutant (but not Par3-A) are phosphorylated in HCT-116 cells.
For details showing evidence of phosphorylation of A-X-A Baz mutant, see Figure S6.
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To validate some aspects of these results, using full-length
PKCi and Par3 in cells we undertook co-immunoprecipitation
experiments of differentially tagged full-length forms of PKCi
and Par3 expressed in transiently transfected HCT-116 cells.
Endogenous PKCi was efficiently immunoprecipitated through
exogenous wild-type Par3, while a full-length human Par3
bearing the site 1 A-X-A mutation showed substantially reduced
interaction with PKCi (Figure 5D), consistent with in vitro data
for the isolated CR3 domain. Note that endogenous PKCi
retains binding to the non-phosphorylatable Par3-S827A (Myc-
PAR-3-A) similarly to the wild-type but is unable to be turned
over and remains tightly associated with PKCi. Reciprocal co-
immunoprecipitation of overexpressed exogenous wild-type
GFP-PKCi efficiently pulled down endogenous Par3, whereas
mutating residues D339PKCi/D382PKCi (GFP-PKCi-D/D) that
directly contact the R7 side chain of Par3 also markedly
reduced the Par3-PKCi interaction (Figure 5E). Arm contacts
identified from the crystal structure are therefore necessary for
Par3 interaction with PKCi. We developed a specific phospho-
Par3 antibody to probe whether mutation of the A-X-A arm
abolished interaction with PKCi completely as well as PKCi-
mediated phosphorylation. While the A-X-A is less phosphory-
lated compared with wild-type (Figure 5F), we noted a large
increase in ubiquitinylated Par3 (under conditions of proteasome
inhibition), a likely consequence of Par3 phosphorylation in non-
polarized cells (data not shown). Taken together, immunocom-
plex recovery fromHCT-116 cells confirmed that (1) the contacts
observed structurally indeed influence interaction in cells as
predicted, and (2) ‘‘weakening’’ the strength of the aPKCi-Par3
interaction through site-specific mutation prevents Par3 inhibi-
tion, leading instead to Par3 phosphorylation.
Apical-Junctional Polarization of Par3/Baz In Vivo Is a
Consequence of Switching between Inhibitory and
Substrate-Binding Modes
If the affinity of the Par3/Baz-aPKC interaction essentially deter-
mines the localization of Par3/Baz in epithelial cells, then the
Par3CR3 substitutions within each arm (A-X-A or A-A-T mutants)
characterized in vitro should affect the localization of Par3/Baz
in vivo. To test this prediction, we mutated the CR3 region of
full-length GFP-tagged Drosophila Baz in the F-X-R motif to
A-X-A or the K-H-T motif to A-A-T and examined their apical
domain or AJ localization in vivo. In the follicular epithelium,
GFP-tagged wild-type Baz (GFP-Baz) co-localizes with aPKC
at the apical membrane and also localizes to AJs (Figure 6A).
Phospho-Baz is known to localize to AJs (Morais-de-Sa et al.,
2010), and a GFP-tagged phosphomimic version of Baz (GFP-
Baz S980E) expectedly fails to co-localize with aPKC at the
apical membrane but instead localizes to AJs (Figure 6B) (Mor-
ais-de-Sa et al., 2010; Walther and Pichaud, 2010). Both the
GFP-Baz A-X-A and A-A-T mutant localize similarly to the phos-
pho-mimetic (Figures 6C, 6D, and 6I), consistent with the view
that lowering affinity (as observed in cells; Figure 5B) and/or
removing inhibitory elements fromCR3 induces phosphorylation
of Baz (as observed in vitro; Figure 5) and therefore results in its
localization to AJs rather than stable Par complex formation at
the apical membrane.
It was important to distinguish betweenwhether the relocaliza-
tion of the Baz A-X-A or A-A-T mutants was due to exposure of392 Developmental Cell 38, 384–398, August 22, 2016the S980 site and phosphorylation as shown in vitro for Par3CR3,
or simply due to a lack of interaction with aPKC. A combined
A-X-A + A-A-T site mutation in vitro showed a complete loss of
interaction of CR3 with PKCi and no phosphorylation of serine
827 (Figure 5A). An equivalent GFP-Baz A-X-A + A-A-T mutant
also localized to AJs (Figures 6H, 6H0, and 6M). Interestingly,
this combined mutant showed distinct intracellular puncta in
which the Baz-GFP mutant no longer overlapped with aPKC,
suggesting that both proteins are mutually exclusive on the
same membrane (Figure 6N).
We then sought to verify whether the A-X-A Baz mutant was
indeed phosphorylated in Drosophila cells. Available phospho-
antibodies against Par3 S827 and Baz S980 were previously
raised against an epitope that included the F-X-R motif and
therefore could not detect the Baz A-X-Amutant or its phosphor-
ylation status (data not shown). Efforts to raise a Baz phospho-
antibody against S980 peptides excluding the F-X-R motif
were not successful. Therefore, we verified that the A-X-A Baz
mutant was phosphorylated in Drosophila cells, by preparing
transfected S2 cell extracts containing wild-type or A-X-A
mutant Baz and probed S980Baz phosphorylation status using
dimethyl labeling and mass spectrometry. Previous efforts to
identify the BazCR3 phospho-site in wild-type and A-X-A mutant
contexts using trypsin digest were unsuccessful due to cleav-
age at R979 and K984, yielding very short peptides. Therefore,
BazCR3 samples were first treated by in-gel reductive dimethyla-
tion, to generate the BazCR3 peptide spanning the sequence
(phospho)SISE(me2K)HHAALDAR. The dimethylation reaction
modifies lysine 3-amino groups, thereby greatly reducing the
ability of trypsin to cleave after lysines. This allowed capture of
the phospho-BazCR3 peptide, facilitated quantification of chro-
matographic peak areas, and identified phospho-peptides. The
forward sample reaction used heavy (CD2O with wild-type Baz
mutant) or light (CH2O with A-X-A Baz) reagents, resulting in a
mass difference of 12 Da and anm/z difference of 4 for the triply
charged target peptide (Figures S6A and S6B). The reverse sam-
ple used heavy (CD2Owith A-X-A Bazmutant) or light (CH2Owith
wild-type Baz) reagents, and two control peptides were also
used to assess any differences in peptide recovery from the
SDS-PAGE gel (Figures S6A and S6C). Recovery was poorer
for all heavy-labeled reverse samples including both controls,
although the data clearly showed that both wild-type and
A-X-A Baz proteins were phosphorylated at S980Baz (Figures
S6C and S6D). Taken together, our data suggest that the
A-X-A mutant can be phosphorylated by aPKC in vitro in
HCT-116 and S2 cells. Moreover, it can be distinguished from
the A-X-A + A-A-T combinedmutant that is no longer a substrate
for aPKC and fails to interact with it both in vitro and in vivo.
We next tested the idea that phosphorylation of Par3/Baz
controls its localization simply by feeding back to block its bind-
ing to aPKC (as observed for phospho-Par3CR3 in vitro; Figure 5).
A GFP-tagged phospho-mutant form of Baz (GFP-Baz S980A)
is known to fail to localize to junctions and instead co-localizes
perfectly with aPKC (Figures 6E, 6J, and S7) (Morais-de-Sa
et al., 2010; Walther and Pichaud, 2010). We find that expres-
sion of this construct also disrupts cellular morphology, consis-
tent with previously reported data (Morais-de-Sa et al., 2010). If
the localization and morphology phenotypes of GFP-Baz S980A
are caused by tight inhibitory binding to aPKC, it should be
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Figure 6. Switching Par3/Baz from Apical to
Junctional In Vivo
(A) GFP-tagged Par3/Baz (green) localizes to the
apical domain (marked by aPKC in red) and also
to AJs.
(B) Phosphomimic GFP-tagged Par3/Baz S980E
(green) is largely excluded from the apical domain
(marked by aPKC in red) and localizes to AJs.
(C) Low-affinity GFP-tagged Par3/Baz F-X-R to
A-X-A mutant (green) is largely excluded from the
apical domain (marked by aPKC in red) and local-
izes to AJs.
(D) Low-affinity GFP-tagged Par3/Baz K-H to A-A
mutant (green) is largely excluded from the apical
domain (marked by aPKC in red) and localizes
to AJs.
(E) Phospho-mutant GFP-tagged Par3/Baz S980A
mutant (green) co-localizes apically with aPKC
(red) and also partially disrupts cell polarity,
consistent with its inhibitory function. See also
Figure S7 for evidence that Baz co-localizes with
aPKC in the absence of kinase activity.
(F) Phospho-mutant GFP-tagged Par3/Baz S980A
that also carries the F-X-R to A-X-A mutation
(green) fails to co-localize with aPKC (red) and
instead localizes to AJs.
(G) Phospho-mutant GFP-tagged Par3/Baz S980A
that also carries the K-H to A-A mutation (green)
fails to co-localize with aPKC (red) and instead
localizes to AJs.
(H) The double mutant K-H to A-A and F-X-R to
A-X-A localizes primarily to AJs.
(I) Apical section of GFP-BazAXA expressing
follicle cell epithelium, showing junctional locali-
zation.
(J–M) Apical section of GFP-BazS980A (J) ex-
pressing follicle cell epithelium, showing mis-
localization to the apical surface. Apical sections of
(K) GFP-BazAXA S980A-, (L) GFP-BazAA S980A-,
and (M) GFP-BazAA AXA-expressing follicle cell
epithelium, showing restoration of junctional
localization.
(N) Non-overlapping punctate localization of GFP-
BazAXA AA (green) with aPKC (red).
DAPI staining is shown in blue in (A)–(H) and (N).
GFP-tagged Par3/Baz is shown in (A0)–(H0).
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Figure 7. Proposed Model for Par3/Baz Antagonism and Polarization
Wepropose two states for PKC-Par3/Baz interaction driven by aPKC kinase domain and Par3/Baz CR3 region. A high-affinity interaction is inhibitory and requires
both arms flanking the PKC consensus motif of the CR3 region. By engaging pockets within both the N and C lobes of aPKC kinase domain, Par3/Baz phos-
phorylation is prevented but Par6-aPKC is recruited to the apical membrane. In an activated state, aPKC is resistant to CR3 antagonism due either to an
inaccessible aC helix pocket or a CR3 interaction being destabilized by phosphorylation of T833Par3 or by aPKC lacking a PDK1-driven T412PKCi phosphorylation.
Either of these possibilities could result in Par3/Baz binding as a substrate exposing its PKC consensus site R-X-S-J to phospho-transfer. Phosphorylated Par3/
Baz is then excluded from the Par complex and thus from the apical membrane domain, and relocalizes to AJs.possible to reverse these phenotypes by introducing either the
F-X-R or K-H-T site mutation to lower the affinity of this interac-
tion. Accordingly, we find that GFP-Baz A-X-A or A-A-T S980A
double mutants fail to co-localize with aPKC and instead
localize to AJs and do not show polarity defects (Figures 6F–
6L). These results strongly support the view that phosphoryla-
tion of Par3/Baz controls its localization through lowering its
binding affinity for aPKC, because the phenotypic consequence
of loss of phosphorylation can be reversed by mutations that
reduce affinity. Consistent with our in vitro data, we propose
that access to the phosphorylation site within Par3/Baz is in394 Developmental Cell 38, 384–398, August 22, 2016turn controlled by modulation of the high-affinity and inhibitory
arms of the CR3 region.
DISCUSSION
Our results reveal the molecular basis for Par3 antagonism of
aPKC through high-affinity inhibitory CR3 arm interactions that
span both N and C lobes of the PKCi kinase domain. Our struc-
tural and biochemical data provide a model that supports a
mechanism explaining apical-junctional polarization of Par3/
Baz in epithelial cells (Figure 7). Previous work has shown that
apical localization of Par3/Baz depends on it being part of the Par
complex, where Par3/Baz is not phosphorylated by aPKC, while
junctional localization of Par3/Baz occurs when it is phosphory-
lated by aPKC (Morais-de-Sa et al., 2010; Walther and Pichaud,
2010). Formation of the Par complex with Par3/Baz is known to
be crucial for apical membrane recruitment of aPKC-Par6 (Gao
et al., 2002).
Here we provide an explanation for why Par3/Baz is not
phosphorylated while engaged within the Par complex even
though it can be phosphorylated when it separates from the
Par complex. Our crystal structure of the Par3 CR3–PKCi kinase
domain interaction reveals the basis for high-affinity Par3CR3
contacts through the coordinated action of two short motifs
flanking the PKC consensus motif R-X-S827-J. Together these
motifs cooperate to inhibit aPKC, one bringing high affinity and
the other enabling inhibitory contacts. The observation that the
same N-lobe pocket is closed in structures of partially primed
PKCiKD-1P with a peptide resembling an aPKC-substrate inter-
action supports a second mode of engagement of Par3. Access
to this N-lobe pocket may dictate whether aPKC-interacting
proteins with an R+5 hook can inhibit aPKC or are phosphory-
lated as substrates. The location of the pocket adjacent to the
aC helix and the aPKC activation loop suggests a potential
mechanism to regulate the decision to engage and phosphory-
late or to be sensitized to Par3 CR3 inhibition in the case of a fully
primed active aPKC conformer.
The precise mechanism determining this switch requires
further study and is beyond the scope of these investigations.
Potential regulatory influences could include the availability of
Par3 inhibitory arms, competition with other aPKC substrates,
the presence of binding partners adjacent to the aPKC aC helix,
post-translational modifications of the Par3CR3 region (such as
T833Par3 phosphorylation by the ROCK kinase), or even regula-
tion of the aPKC activation loop (by PDK1 or by dephosphor-
ylation by an unknown A-loop phosphatase). One or more of
these factors, depending on the physiopathological status of
the epithelium, could affect the Par3-binding mode. We do
note that Kibra (and its homologWWC2) contains an F-X-R motif
and a K-R-T hook flanking its known aPKC phosphorylation site
(between residues 911 and 978), suggesting that it too could act
as dual-action inhibitor/substrate, consistent with biochemical
data (Figure S5) (Yoshihama et al., 2011). Similarly, many known
aPKC substrates have an adjacent F-X-R motif, for example,
Par1, Par2, and ROCK kinase, suggesting that the F-X-R may
provide specificity and an affinity boost to these validated
aPKC substrates (Hurov et al., 2004; Ishiuchi and Takeichi,
2011; Motegi et al., 2011; Suzuki et al., 2004).
Our evidence indicates that engineered lower-affinity interac-
tions between the Par3/Baz CR3 domain and the aPKC kinase
domain result in Par3/Baz CR3 phosphorylation (Figures 5A–
5C). Mutation of either the F-X-R or K-H-T site that our structure
shows are important for a high-affinity inhibitory interaction leads
to a relocalization of Par3/Baz away from the apical domain
(where the Par complex resides) to AJs, similar to a phospho-
mimetic S980E mutant in Par3/Baz (Figures 6A–6D). Combining
both mutations further lowers the affinity, leading to a form of
Par3/Baz unable to engage aPKC that cannot be phosphory-
lated by it. Such a mutant Par3/Baz also relocalizes to AJs.
Thus, Par3/Baz that fails to form a stable inhibitory Par complexwill localize to AJs either through aPKC-mediated phosphoryla-
tion or through a loss of interaction.
Why does phosphorylation of Par3/Baz cause its localization
to AJs? Our findings show that phospho-Par3/Baz dramatically
reduces its affinity for aPKC and thus the phosphorylation event
precludes it from joining the Par complex. Phosphomimic S980E
Par3/Baz is known to localize to AJs, just like the affinity-lowering
A-X-A or A-A-T mutants of Par3/Baz (Figure 6). Furthermore, the
behavior of phospho-resistant mutant S980A Par3/Baz (which
only localizes with aPKC) can be reversed in A-X-A S980A or
A-A-T S980A double mutant Par3/Baz (which only localizes to
AJs) (Figure 6). Previous studies have proposed that the AJ local-
ization of Par3/Baz results from exclusion from the apical domain
upon aPKC phosphorylation combined with exclusion from the
basolateral domain upon Par1 phosphorylation (Tepass, 2012).
Taken together, our data stimulate a model in which aPKC-
driven phosphorylation of Par3/Baz can be recapitulated simply
by weakening the Par3/Baz interaction affinity by manipulating
the sequences flanking the consensus PKC phosphorylation
site (Figure 7).
Our findings implicate both Par3/Baz and Kibra as aPKC inhib-
itors that are also known substrates. An analogous situation
arises for LGL, a known inhibitor of aPKC that is also phosphor-
ylated at multiple serine sites (Bailey and Prehoda, 2015). There
are also precedents for protein kinase dual-action inhibitor/sub-
strates. The protein kinase A (PKA) regulatory subunit RIIb has an
RRXS motif that is phosphorylated by PKA, leading to its stable
association with and inhibition of PKA (Zhang et al., 2015). In this
context the modification functions as part of a single-turnover
phosphoryl transfer reaction. For Par3 and other F-X-R-contain-
ing proteins, a different role is likely whereby phosphorylation by
aPKC provokes Par3/Baz dissociation, as shown in vitro using
CR3 peptides and in vivo using phospho-mimetics. Another
example is the cyclin-dependent kinase inhibitors p21/p27/
KIP, which are able to both inhibit cyclin-dependent kinases as
well as being efficient substrates (Russo et al., 1996).
Our findings suggest that aPKC is inhibited by Par3/Baz
within the Par complex, yet it is known that the Par complex
contains active aPKC kinase and can phosphorylate many
substrates (such as Lgl and Par1 in Drosophila epithelia and
Caenorhabditis elegans zygotes, and Miranda in Drosophila
neuroblasts). One possible explanation for this open issue is
that discrete functional states of the Par complex (Par6-
aPKC-Cdc42-Par3) may exist. Par3-dependent recruitment of
aPKC to apical membranes may evoke a higher-order oligomer
consistent with known Par3 CR1-dependent oligomers (Benton
and St Johnston, 2003a). Conversely, phosphorylation of
T833Par3 by ROCK kinase or a lack of T412PKCi phosphorylation
by PDK1 would generate functionally distinct forms of the Par
complex, unable to be inhibited by Par3 CR3 as discussed
earlier. Equally, association of partner proteins close to the
aPKC aC helix could also block the formation of an R+5 pocket
and prevent CR3-mediated inhibition. Therefore, further exper-
iments are required to characterize precisely which polarity
signal(s) provoke Par3 phosphorylation by overcoming CR3
antagonism.
In conclusion, our findings provide a molecular basis for
Par3-mediated antagonism of aPKC that affects apical versus
junctional polarization of Par3/Baz in epithelia.Developmental Cell 38, 384–398, August 22, 2016 395
EXPERIMENTAL PROCEDURES
Protein Construct Design, Expression, and Purification
Mammalian plasmids pEGFP-PKCi-WT, pEGFP-PKCi-DD/AA (D339A/
D382A), pK-myc-Par3-WT (Addgene, plasmid 19388), pK-myc-Par3-AXA
(F818A/R820A), and pK-myc-Par3-A (S827A) included human PKCi and Par3
cDNAs. Mutagenesis of PKCi and Par3 was performed using QuikChange
(Stratagene). Recombinant human PKC-iota kinase domain (PKCiKD) was pre-
pared using a baculovirus encoding residues 248–596 (GenBank: NM_002740.
5), fused to a glutathione S-transferase (GST) tag as described previously
(Kjaer et al., 2013). See Supplemental Experimental Procedures for a detailed
description. In brief, the protein was expressed in Hi5 cells by co-infection
with the above virus and a PDK-1 virus using standard protocols (Oxford
Expression Technology). The GST tag was used for affinity purification and
removed by 3C protease cleavage using standard protocols. Two distinct
phospho-species PKCiKD-2P and PKCiKD-1P were separated by ion-ex-
change chromatography (Hi-Trap Q column, GE Healthcare).
Enzymatic Assay and Fluorescence Anisotropy Binding Assay
The ADP Quest kit (DiscoveRx) was used to determine the kcat app and KM app
values for ATP against the PKCiKD-1P and PKCiKD-2P using a series of syn-
thetic peptide substrates as described by Kjaer et al. (2013). The reactions
were measured every 2 min for 30 min in a 384-well plate using a Safire2 plate
reader (Tecan). The kinetic constants were determined by fitting the data to the
Michaelis-Menten equation. Data are represented as mean ± SEM. Fluores-
cence anisotropy assays were performed to determine the KD for each peptide
labeledwith a fluorescein tag following standard protocols using a Safire2 plate
reader (Tecan). The anisotropy values were normalized and the KD was deter-
mined using non-linear regression. All experimentswere performed in triplicate
and for at least three independent protein preparations.
Structure Determination of Nucleotide-Bound PKCiKD-2P
Complexes
PKCiKD-2P was incubated with a 3-molar excess of nucleotide or analog with
either Mg2+ or Mn2+ (see Table 1) and a 3-molar excess of peptide. Crystalliza-
tion was performed using the hanging-dropsmethodwith 1:1 ratio of protein to
precipitant at 20C. X-ray data were collected at synchrotrons as specified by
Table 1 and data were processed using either XDS (Kabsch, 2010b) and
Xscale (Kabsch, 2010a) or D*Trek (Pflugrath, 1999) and Scala/Pointless
(Collaborative Computational Project-Number 4, 1994). Structures were deter-
mined by molecular replacement performed using Phaser (McCoy et al., 2007)
using a previous PKC i-2P structure as a search model (PDB: 3A8W). Refine-
ment was carried out in Phenix (Adams et al., 2010) with cycles of model build-
ing in Coot (Emsley and Cowtan, 2004).
Cell Culture and Transfection
HCT-116 cells grown in McCoy’s 5A medium containing 10% bovine fetal calf
serum and penicillin/streptomycin (Invitrogen) were transfected (10-mg portion
of DNA or 5-mg + 5-mg portions of DNA for co-transfections) using Fugene HD
(Roche) according to the manufacturer’s instructions. The cells were then
grown in normal medium for 36 hr.
Antibodies, Immunoprecipitation, and Immunoblotting
The following antibodies were used for immunoblotting: mouse monoclonal
anti-PKCi (recognition for human PKCi), mouse monoclonal anti-Myc (9 3
1010), rabbit polyclonal anti-Par3 (Millipore), and rabbit polyclonal anti-GFP
antibody (Santa Cruz Biotechnology). Anti-phospho-S827 Par3 antibody
was raised in-house using an antigen lacking the F-X-R site of Par3CR3. Immu-
noprecipitation and immunoblotting was carried out as described in Supple-
mental Experimental Procedures.
Dimethyl Labeling and Quantification of Bazooka Wild-Type and
Mutant S980 Phosphorylation in S2 Cell Extracts
After SDS-PAGE, in-gel stable isotope dimethyl labeling was performed
according to published protocols. The heavy reaction was performed using
13CD2O formaldehyde creating a mass difference of 6 Da per primary amine
group between heavy and light dimethylated peptides. After extensive
washing of gel pieces, the in-gel dimethylated proteins were then subjected396 Developmental Cell 38, 384–398, August 22, 2016to overnight in-gel trypsin digestion at 37C. The following day peptides
were extracted and subjected to another round of reductive dimethylation
reactions aimed at methylating peptide N termini. Peptide mixtures were
acidified and prepared for liquid chromatography-mass spectrometry anal-
ysis using an Ulimate3000 high-performance liquid chromatograph coupled
to a Q-Exactive mass spectrometer (Thermo Fisher). A targeted scan was
performed for the S980-containing peptides and this was alternated with a
top-10 data-dependent acquisition scan. Mascot-generated DAT files were
converted to Skyline-compatible biblio.spec libraries, and heavy and light
peak areas were extracted by Skyline software version 2.5.0.6079 (MacLean
et al., 2010).
Drosophila Genetics and Oligonucleotides
Expression of UAS-driven transgenes in follicle cells was achieved with the
GR1.Gal4 line. UAS.GFP-Baz lines were constructed by mutagenizing the
full-length Baz cDNA in pDONR, followed by transfer to the pPGW (pUASP-
EGFP-Gateway) vector for transgenesis (Bestgene). The UAS.GFP-BazS980E
line was a gift from F. Pichaud. Primers used for mutagenesis are described in
Supplemental Experimental Procedures.
Drosophila Antibodies and Immunohistochemistry
Ovaries were dissected in PBS, fixed for 20 min in 4% paraformaldehyde in
PBS, washed for 30 min in PBS/0.1% Triton X-100 (PBST), and blocked for
15 min in 5% normal goat serum/PBST (PBST/NGS). Primary antibodies
were diluted in PBST/NGS and samples were incubated overnight at 4C.
Either optical cross-sections through the middle of egg chambers or apical
sections of the follicular epithelium are shown. Primary antibodies used are
described in Supplemental Experimental Procedures.
ACCESSION NUMBERS
Coordinates and structure factors for PKCiKD-2P-Par3CR3, PKCiKD-2P-
FXRshort peptide, and nucleotide-bound PKCiKD-2P have been deposited in
the PDB with the accession numbers PDB: 5LI1, 5LIH, and 5LI9, respectively.
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